New foam treatment for kids with psoriasis enters early testing

NCT ID NCT07340216

Recruiting now Symptom relief Sponsor: Arcutis Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 15, 2026 · Updated 11 times

Summary

This study tests a medicated foam called ARQ-154 in 16 children aged 2 to 12 with psoriasis on their scalp and body. The goal is to see how much of the drug enters the blood and if it is safe. Participants apply the foam daily for several weeks, and doctors monitor side effects and depression symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arcutis Clinical Study Site 104
RECRUITING

Arlington, Texas, 76011, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Arcutis Clinical Study Site 105
RECRUITING

West Lafayette, Indiana, 47906, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Arcutis Clinical Study Site 106
RECRUITING

Bryant, Arkansas, 72022, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Arcutis Clinical Study Site 107
RECRUITING

Miami Lakes, Florida, 33014, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Arcutis Clinical Study Site 108
RECRUITING

Meridian, Idaho, 83646, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PSORIASIS